Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - September 15, 2026 41 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis of the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR Patient Exposure to Anticancer Drugs Subsequently Withdrawn from the FDA Accelerated... March 9, 2023 Neoadjuvant Toripalimab Combined with Axitinib Demonstrates a Promising Pathologic Response Rate... December 5, 2023 Community Comes Together To Give Terminally Ill Father One Last Christmas... October 18, 2021 Coffee Shop Owner Learns He Has Terminal Cancer – So Competitor... February 11, 2020 Load more HOT NEWS Giving Birth Before Age 20 Cuts Breast Risk By 50%, And... Simple Hysterectomy Noninferior to Radical Hysterectomy with Respect to Pelvic Recurrence... The National Parks Service Still Hasn’t Fixed It’s Sexual Harassment Problem Remembering With Gratitude
